We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A former senior executive at a major multinational drugmaker in India has
urged the local industry not to hesitate in complying with new manufacturing
rules.
Elite Pharmaceuticals and IntelliPharmaCeutics (Toronto, Canada), a privately
held, specialty pharmaceutical company, announced today that they have entered
into an agreement for the development of a generic, controlled release drug
product with an addressable market in the U.S. of approximately $4 billion in
2004.
Biolitec AG today announced that it has obtained an exclusive worldwide license
for development and commercialization of innovative drug formulations using
the Pegylated liposome technology of Valentis of Burlingame, CA, through its
associate, Biolitec Pharma Marketing.
Generex Biotechnology Corporation today announced that a research collaboration
agreement has been signed by its subsidiary Antigen Express with Stallergenes,
S.A. a major European firm in immunological treatments for allergy and asthma.
ML Laboratories is buying pulmonary drug formulation specialist Quadrant Technologies
Ltd. for £46.7 million (US$85 million) in cash and shares, and changing
its name to Innovata plc to reflect the transformation the acquisition will
bring.
According to reports in the US media, a number of African states
have rejected consignments of antiretroviral (ARV) drugs supplied under the
PEPFAR initiative for HIV/AIDS pandemic areas.
A coalition of NGOs is due to meet with representatives from
three major drugmakers in Brazil today, amid the continued threat of the violation
of patents on key ARV drugs.